HIGHLIGHTS
- who: Muhammad Arslan* from the Middle East Technical University, Ankara, Turkey have published the research: siRNA-Induced Silencing of LP(a) Gene: An Ideal Choice to Prevent Genetic Risk of Myocardial Infarction, in the Journal: (JOURNAL)
- what: CVDs are the most common diseases of today`s world and MI is one of leading causes of death among CVD patients.
SUMMARY
Amgen`s Olpasiran (also known as AMG 890) which is first-inclass N-acetylglucosamine (GalNAc)-conjugated siRNAbased therapy has shown potential effects on reducing the genetic risk of MI by inhibiting . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.